Financials data is unavailable for this security.
View more
Year on year Jiangsu Kanion Pharmaceutical Co Ltd grew revenues 11.88% from 4.35bn to 4.87bn while net income improved 23.54% from 434.47m to 536.73m.
| Gross margin | 73.12% |
|---|---|
| Net profit margin | 12.30% |
| Operating margin | 12.03% |
| Return on assets | 8.11% |
|---|---|
| Return on equity | 10.73% |
| Return on investment | 10.64% |
More ▼
Cash flow in CNYView more
In 2023, Jiangsu Kanion Pharmaceutical Co Ltd increased its cash reserves by 23.17%, or 370.95m. The company earned 1.04bn from its operations for a Cash Flow Margin of 21.39%. In addition the company used 540.31m on investing activities and also paid 129.81m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 8.85 |
|---|---|
| Tangible book value per share | 8.15 |
More ▼
Balance sheet in CNYView more
| Current ratio | 2.60 |
|---|---|
| Quick ratio | 2.22 |
| Total debt/total equity | 0.00 |
|---|---|
| Total debt/total capital | 0.00 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 69.10% and 23.39%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
| Div yield(5 year avg) | 0.88% |
|---|---|
| Div growth rate (5 year) | 35.99% |
| Payout ratio (TTM) | 39.69% |
| EPS growth(5 years) | 5.85 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 7.08 |
More ▼
